Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality
Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality
ABSTRACT Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 remains a global threat with few proven efficacious treatments. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA). We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality. We here present results from 60-day follow up of our cohort of 351 transfused hospitalized patients. Prospective determination of ELISA anti-RBD IgG titer facilitated selection and transfusion of the highest titer units available. Retrospective analysis by the Ortho VITROS IgG assay revealed a median signal/cutoff (S/C) ratio of 24.0 for transfused units, a value far exceeding the recently FDA-required cutoff of 12.0 for designation of high titer convalescent plasma. With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma. In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.
Olsen Randall J.、Gollihar Jimmy、Nguyen Duc T.、Castillo Brian、Chen Jian、Lopez Bevin Valdez、Joseph David、Musser James M.、Zhao Picheng、Leveque Christopher、Bernard David W.、Christensen Paul A.、Masud Faisal、Yi Xin、Graviss Edward A.、Shehabeldin Ahmed、Salazar Eric、Eagar Todd N.、Rogers John
Department of Pathology and Genomic Medicine, Houston Methodist Hospital||Department of Pathology and Laboratory Medicine, Weill Cornell Medical College||Center for Molecular and Translational Human Infectious Diseases, Houston Methodist Research InstituteCCDC Army Research Laboratory-South, University of Texas at AustinCenter for Molecular and Translational Human Infectious Diseases, Houston Methodist Research InstituteDepartment of Pathology and Genomic Medicine, Houston Methodist HospitalDepartment of Pathology and Genomic Medicine, Houston Methodist HospitalAcademic Office of Clinical Trials, Houston Methodist Research InstituteDepartment of Pathology and Genomic Medicine, Houston Methodist HospitalDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital||Department of Pathology and Laboratory Medicine, Weill Cornell Medical College||Center for Molecular and Translational Human Infectious Diseases, Houston Methodist Research InstituteDepartment of Pathology and Genomic Medicine, Houston Methodist HospitalDepartment of Pathology and Genomic Medicine, Houston Methodist HospitalDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital||Department of Pathology and Laboratory Medicine, Weill Cornell Medical CollegeDepartment of Pathology and Genomic Medicine, Houston Methodist HospitalDepartment of Anesthesiology and Critical Care, Houston Methodist HospitalDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital||Department of Pathology and Laboratory Medicine, Weill Cornell Medical CollegeDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital||Center for Molecular and Translational Human Infectious Diseases, Houston Methodist Research InstituteDepartment of Pathology and Genomic Medicine, Houston Methodist HospitalDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital||Department of Pathology and Laboratory Medicine, Weill Cornell Medical CollegeDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital||Department of Pathology and Laboratory Medicine, Weill Cornell Medical CollegeDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital
医药卫生理论医学研究方法临床医学
Olsen Randall J.,Gollihar Jimmy,Nguyen Duc T.,Castillo Brian,Chen Jian,Lopez Bevin Valdez,Joseph David,Musser James M.,Zhao Picheng,Leveque Christopher,Bernard David W.,Christensen Paul A.,Masud Faisal,Yi Xin,Graviss Edward A.,Shehabeldin Ahmed,Salazar Eric,Eagar Todd N.,Rogers John.Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality[EB/OL].(2025-03-28)[2025-06-04].https://www.medrxiv.org/content/10.1101/2020.10.02.20206029.点此复制
评论